Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG-008 in advanced solid tumors with specific genetic alterations
NCT04518137Phase 2Terminated
- Sponsor
- Antengene
- Start
- Apr 2021
- Primary completion
- May 2022
- Countries
- 1
01
Overview
A Phase 2 trial of onatasertib in solid tumor (advanced stage), sponsored by Antengene. Started Apr 2021; status: terminated.
02
Drugs
onatasertib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04518137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04518137.